e-ISSN 2329-0072


Get your full text copy in PDF

GnRH Antagonist Protocol Is It an Optimal Protocol for Policytic Ovary Syndrome (PCOS) Patients Undergoing In Vitro Fertilisation (IVF)/Intracytoplasmic Sperm Injection (ICSI)?

Weijie Xing, Haiyan Lin, Yu Li, Dongzi Yang, Qingxue Zhang

(Center for Reproductive Medicine, 3rd Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China (mainland))

Med Sci Tech 2017; 58:10-14

DOI: 10.12659/MST.903594

BACKGROUND: Polycystic ovary syndrome (PCOS) is a very common heterogeneous disorder. PCOS affects about 5–10% of reproductive-age infertile women. Several controlled ovarian hyperstimulation (COH) protocols can be used for patients with PCOS; however, the optimal stimulation protocol is still under debate. The present study aimed to determine if the GnRH antagonist protocol is an optimal protocol for patients with PCOS.
MATERIAL AND METHODS: We retrospectively analyzed 983 IVF-ET/ICSI cycles in PCOS patients from 2012 to 2014. There were 2 groups in this study: the GnRH agonist (GnRH-a) group and the GnRH antagonist (GnRH-ant) group. The stimulation materials, IVF outcomes, and the rate of complications were compared.
RESULTS: In the GnRH-a group, the duration of stimulation was 12.35±3.10 days and the total doses of Gn were 1882.20±814.53 IU, which were significantly more than those in the GnRH-ant group (10.52±3.26 days and 1480.04±660.74 IU, P<0.001). The rate of ovarian hyperstimulation syndrome (OHSS) in the GnRH-ant group was slightly lower than in the GnRH-a group (3.42% vs. 4.84%, P=0.406). The cycle clinical pregnancy rate and implantation rate in the GnRH-ant group were all significantly lower than in the GnRH-a group (31.59% vs. 44.68%, 48.91% vs. 63.13%, P<0.001).
CONCLUSIONS: For patients with PCOS, the GnRH-a protocol outperformed the GnRH-ant protocol according to the cycle clinical pregnancy rate and implantation rate. However, the GnRH-ant protocol in part can lower the incidence of OHSS.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree